Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL

BACKGROUND: Lapatinib has clinical efficacy in the treatment of trastuzumab-refractory HER2-positive breast cancer. However, a significant proportion of patients develop progressive disease due to acquired resistance to the drug. Induction of apoptotic cell death is a key mechanism of action of lapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Eustace, Alex J, Conlon, Neil T, McDermott, Martina S J, Browne, Brigid C, O’Leary, Patrick, Holmes, Frankie A, Espina, Virginia, Liotta, Lance A, O’Shaughnessy, Joyce, Gallagher, Clair, O’Driscoll, Lorraine, Rani, Sweta, Madden, Stephen F, O’Brien, Neil A, Ginther, Charles, Slamon, Dennis, Walsh, Naomi, Gallagher, William M, Zagozdzon, Radoslaw, Watson, William R, O’Donovan, Norma, Crown, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180577/
https://www.ncbi.nlm.nih.gov/pubmed/30305055
http://dx.doi.org/10.1186/s12885-018-4852-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180577/
https://www.ncbi.nlm.nih.gov/pubmed/30305055
http://dx.doi.org/10.1186/s12885-018-4852-1

Ejemplares similares